Education
About Us
Working with TipRanks
Follow Us
BeiGene Ltd (HK:6160)
:6160
Earnings Data
Report Date
Aug 22, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.15Last Year’s EPS
-0.69Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 0.91%
|Next Earnings Date:Aug 22, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong business performance with record revenue growth, market leadership in key areas, and significant progress in its R&D pipeline. Despite some challenges in fixed duration regimens and impacts from Medicare Part D redesign, the company demonstrated resilience and strategic foresight.Company Guidance
During the call, BeiGene provided a comprehensive update on their first quarter of fiscal year 2025, highlighting significant achievements across their business priorities. They reported a revenue of $1.1 billion, marking a 49% growth from Q1 2024, with BRUKINSA sales reaching $792 million, a 62% increase year-over-year. The company achieved GAAP profitability for the first time, driven by strong commercial performance across major markets, including a 60% growth in the U.S. and 75% in Europe. BeiGene's pipeline progress was underscored by the completion of enrollment in the Phase III CELESTIAL trial for sonrotoclax (sonro) in CLL, and plans to submit global filings in the second half of the year. Additionally, they highlighted the advancement of their BTK CDAC program, which has dosed over 600 patients and is moving into Phase III trials. The call also emphasized BeiGene's strategic investments in global manufacturing, including an $800 million facility in Hopewell, New Jersey, enhancing supply chain resilience. The company reaffirmed its full-year 2025 guidance, projecting revenue between $4.9 billion and $5.3 billion, with continued focus on expanding their oncology leadership and delivering value for patients and shareholders.Record Revenue Growth
Global sales reached $1.1 billion, marking a 49% increase from Q1 2024. The U.S. market grew by 60%, with BRUKINSA driving significant growth.
BRUKINSA Market Leadership
BRUKINSA achieved market leader status in the U.S. BTK market with quarterly sales of $563 million, growing 60% year-over-year.
Global Expansion and Approvals
TEVIMBRA was approved for frontline ESCC in the U.S., and the company expanded its global reach with launches in over 80 markets.
GAAP Profitability
BeiGene achieved GAAP profitability for the first time, with a strong increase in net income and operating cash flow.
Progress in R&D Pipeline
Significant advancements in the hematology and solid tumor pipelines, including the initiation of new Phase III trials for BTK CDAC and other promising assets.
HK:6160 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HK:6160 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | HK$153.20 | HK$141.00 | -7.96% |
Mar 27, 2025 | HK$151.70 | HK$159.60 | +5.21% |
Nov 12, 2024 | HK$125.20 | HK$121.80 | -2.72% |
Aug 27, 2024 | HK$120.90 | HK$121.80 | +0.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BeiGene Ltd (HK:6160) report earnings?
BeiGene Ltd (HK:6160) is schdueled to report earning on Aug 22, 2025, TBA Not Confirmed.
What is BeiGene Ltd (HK:6160) earnings time?
BeiGene Ltd (HK:6160) earnings time is at Aug 22, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of BeiGene Ltd stock?
The P/E ratio of BeiGene Ltd is N/A.
What is HK:6160 EPS forecast?
HK:6160 EPS forecast for the fiscal quarter 2025 (Q2) is 0.15.